Sarepta Therapeutics has halted shipments of its FDA-approved Duchenne muscular dystrophy gene therapy Elevidys for non-ambulatory patients following the second recent death from acute liver failure. Both deceased patients were non-ambulatory individuals who developed liver failure post-treatment. Sarepta is convening an independent panel of experts to evaluate an enhanced immunosuppressive regimen incorporating sirolimus, aiming to mitigate liver toxicity for this vulnerable group. The company is collaborating with the FDA on updated treatment protocols as patient safety remains paramount.